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ABSTRACT
The prognosis of patients with primary refractory acute myelogenous leukemia (AML) is poor. Our initial
report suggested that some patients could achieve durable remission after allogeneic stem cell transplantation
(SCT). Herein, we update our initial experience and report further analysis of this group of patients to
determine whether there are pre-SCT prognostic factors predictive of posttransplantation relapse and survival.
We reviewed the records of 68 patients who consecutively underwent transplantation at the City of Hope
Cancer Center with allogeneic SCT for primary refractory AML between July 1978 and August 2000. Potential
factors associated with overall survival and disease-free survival were examined. With a median follow-up of 3
years, the 3-year cumulative probabilities of disease-free survival (DFS), overall survival (OS), and relapse rate
for all 68 patients were 31% (95% confidence interval [CI], 20%-42%), 30% (95% CI, 18%-41%), and 51%
(95% CI, 38%-65%), respectively. In multivariate analysis, the only variables associated with shortened OS and
DFS included the use of an unrelated donor as the stem cell source (relative risk, 2.23 [OS] and 2.05 [DFS]; P
.0005 and .0014, respectively) and unfavorable cytogenetics before SCT (relative risk: 1.68 [OS] and 1.58
[DFS]; P  .0107 and .0038, respectively). Allogeneic SCT can cure approximately one third of patients with
primary refractory AML. Cytogenetic characteristics before SCT correlate with transplantation outcome and
posttransplantation relapse.
© 2003 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
The survival of patients with acute myelogenous
eukemia (AML) who do not achieve a remission with
rimary induction therapy is poor. After induction
ith conventional chemotherapy regimens, such as
he combination of 3 days of anthracycline and 7 days
f conventional-dose cytarabine (100-200 mg/m2/d), t
66pproximately 30% of patients will not achieve a re-
ission [1]. Of this group, selected patients may still
espond to a high-dose cytarabine-based (2-3 g/m2)
alvage regimen, but cure is rare [2]. Our initial report
ncluded 14 patients with primary refractory AML and
trongly suggested that some patients can achieve du-
able remission after allogeneic stem cell transplanta-characteristics Treatment failure
oi:10.1016/j.bbmt.2003.08.004ion (SCT) [3]. Data from the International Bone
Marrow Transplant Registry (n  88) [4] and the
Socie´te´ Franc¸aise de Greffe de Moelle (n  69) [5]
reported a 3-year disease-free survival (DFS) of 21%
and 9%, respectively, for similar patients. On the basis
of these reports, allogeneic SCT has become a treat-
ment option for patients with primary refractory
AML, but few series have analyzed the prognostic
factors that determine transplantation outcome. In
this study, we updated our initial experience to include
68 patients with primary refractory AML who under-
went transplantation in the City of Hope BMT pro-
gram. We analyzed this group of patients to deter-
mine whether there are pre-SCT features that predict
treatment failure after transplantation.
PATIENTS AND METHODS
We reviewed the records of 68 patients who con-
secutively underwent transplantation at the City of
Hope Comprehensive Cancer Center with allogeneic
SCT for primary refractory AML from July 1978 to
August 2000. This study was approved by the institu-
tional review board according to institutional standard
practice. Patients were eligible for this study if they
had never achieved a ﬁrst complete remission with
chemotherapy. Complete remission was deﬁned as
5% blasts in the bone marrow and normalization of
the peripheral blood count without circulating blasts.
Patients were not eligible for allogeneic SCT if they
had severe concomitant medical or psychiatric ill-
nesses, had active central nervous system leukemia, or
were seropositive for human immunodeﬁciency virus
or human T-cell lymphoma virus-1. Other exclusion
criteria included a bilirubin level 2 mg/dL, a creat-
inine clearance 80 mL/min, a cardiac ejection frac-
tion of 50%, and a forced expiratory volume in 1
second and/or diffusing lung capacity 50% of the
predicted value.
Cytogenetic risk group analysis was performed
according to Southwest Oncology Group guidelines
[6]. Three cytogenetic categories were deﬁned. The
favorable-risk category included patients with abnor-
malities of inv(16)/t(16;16) or t(15;17) with any addi-
tional abnormalities or t(8;21) without either having a
del(9q) or being part of a complex karyotype. The
intermediate-risk category included patients charac-
terized by 8, Y, 6, del(12p), or a normal karyo-
type. The unfavorable-risk category was deﬁned by
the presence of 1 or more of 5/del(5q); 7/del(7q);
inv(3q); abnormal 11q, 20q, or 21q; del(9q); t(6;9);
t(9;22); abnormal 17p; and a complex karyotype, de-
ﬁned as 3 abnormalities.
Factors associated with overall survival (OS) and
DFS were examined by univariate Cox regression
analysis. The risk ratio was calculated for each variable
tested, along with the 95% conﬁdence interval (CI).
Stepwise Cox regression was performed to determine
independent predictors of relapse and survival; all
variables with P  .10 on univariate analysis were
included as candidates in the analysis. Survival esti-
mates were calculated on the basis of the product-limit
method of Kaplan and Meier, and comparisons be-
tween subgroups were made with the log-rank test.
The 95% CIs were calculated by using the logit trans-
formation and the Greenwood variance estimate. The
Wilcoxon ranked sum test was used in comparing
medians for continuous data, and the Pearson 2 test
was used to compare the incidence of graft-versus-
host disease (GVHD) between treatment regimens.
The following variables were examined for their effect
on outcome: age at transplantation, sex, white blood
cell count (WBC) at diagnosis, number of cycles of
induction chemotherapy, treatment with high-dose
cytarabine-based regimens, WBCs before transplan-
tation, cytogenetic risk group, percentage of blasts in
blood or bone marrow at the time of the transplanta-
tion, conditioning regimen (total body irradiation
[TBI] based versus chemotherapy based), and interval
between diagnosis and transplantation.
RESULTS
Patient Characteristics and Outcome
The demographic data and disease characteristics
are shown in Table 1. The median age at SCT was 37
years (range, 2-62 years). Sixty percent of patients
experienced treatment failure with at least 1 cycle of a
high-dose cytarabine-based regimen, and 60% re-
ceived at least 2 prior regimens before SCT. The
median interval from diagnosis to SCT was 3.3
months (range, 0.8-10.3 months). The median per-
centage of blasts in the bone marrow was 36% (range,
1% to 90%). Fifty (74%) patients had evaluable
pretransplantation cytogenetics categorized as fol-
lows: 2 had favorable, 27 intermediate, and 21 unfa-
vorable cytogenetics. Fifty-two patients (76%) re-
ceived a TBI-based conditioning regimen. Fifty-six
patients (82%) received stem cells from matched re-
lated donors and 12 (18%) from matched unrelated
donors. All patients received unmodiﬁed bone marrow
or granulocyte colony-stimulating factor–primed pe-
ripheral blood stem cells. During the study period,
patients were also enrolled in ongoing GVHD pro-
phylaxis studies [7,8]. GVHD prophylaxis consisted of
cyclosporine and prednisone in 28%; cyclosporine and
methotrexate in 19%; cyclosporine, prednisone, and
methotrexate in 26%; and others in 26%.
For patients who survived to the date of analysis,
follow-up ranged from 1 to 18 years, with a median of
3 years. At the time of this analysis, 18 patients were
alive and in continuous remission. Twenty-eight pa-
tients had a relapse (median time to relapse, 9.3
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months; range, 0.9-43.5 months), and 22 died of non-
relapse causes. Most of the relapses (27/28; 96%)
occurred within the ﬁrst year after SCT.
The 3-year cumulative probabilities of DFS, OS,
and relapse rate (RR) for all 68 patients were 31%
(95% CI, 20%-42%), 30% (95% CI, 18%-41%), and
51% (95% CI, 38%-65%; Figures 1 and 2). The
3-year probabilities of DFS and RR at 3 years were
44% (95% CI, 25%-63%) and 37% (95% CI, 17%-
58%), respectively, for patients with intermediate cy-
togenetics and 18% (95% CI, 1%-35%) and 57%
(95% CI, 31%-83%), respectively, for patients with
unfavorable cytogenetics (Figures 3 and 4). The dif-
ferences in DFS and OS between the 2 groups were
signiﬁcant by log-rank test (P  .0071 and P  .0147,
respectively). The difference in probability of relapse
was also signiﬁcant (P  .0264 by the Wilcoxon test).
The DFS for related donors (n  56) and unrelated
donors (n  12) was 36% and 8%, respectively (log
rank; P  .0005; Figure 5).
Prognostic Factors
Univariate and multivariate stepwise Cox propor-
tional hazard analyses of patient characteristics were
performed to determine risk factors for OS and DFS.
In the multivariate stepwise model, the only variables
associated with shortened OS and DFS included the
use of an unrelated donor as the stem cell source
Figure 1. Overall and disease-free survival (n  68).
Figure 2. Time to relapse for all 68 patients with primary refractory
AML.
Figure 3. Kaplan-Meier disease-free survival for patients with in-
termediate and unfavorable cytogenetics.
Table 1. Patient Characteristics and Transplantation Procedures
Variable n (%)
Patient Characteristics
Age
<30 y at transplant 17 (25)
>30 y at transplant 51 (75)
Sex
Male 34 (50)
Female 34 (50)
Prior treatment with High-dose
cytarabine-based regimen
Yes 41 (60)
No 27 (40)
No. of prior regimens
<2 56 (82)
>2 12 (18)
Transplantation characteristics
Related Donor
Genotypic-identical 54 (79)
Phenotypic-identical 2 (3)
Unrelated donor
HLA-identical 7 (10)
HLA mismatched 5 (7)
Conditioning regimen
FTBI  cyclophosphamide  others 17 (25)
FTBI  busulfan  VP-16 16 (24)
FTBI  busulfan 12 (17)
Busulfan  cyclophosphamide 6 (9)
Others 4 (6)
GVHD prophylaxis
CSA alone 1 (1)
CSA  Pred 19 (28)
CSA  MTX 13 (19)
CSA  Pred  MTX 18 (26)
Others 17 (26)
CSA indicates cyclosporine; Pred, prednisone; MTX, methotrexate;
FTBI, fractionated total body irradiation.
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(relative risk, 2.23 [OS] and 2.05 [DFS]; P .0005 and
.0014, respectively) and unfavorable cytogenetics be-
fore SCT (relative risk, 1.68 [OS] and 1.58 [DFS]; P
.0107 and .0038, respectively). Age at transplantation,
sex, WBCs at diagnosis, number of cycles of induction
chemotherapy, prior treatment with high-dose cytara-
bine-based regimens, pretransplantation WBCs, per-
centage of blasts in the blood or bone marrow before
SCT, conditioning regimens (TBI based versus che-
motherapy based), and the interval between diagnosis
and SCT did not affect DFS or RR.
The 38 patients who survived in remission to day
100 were analyzed to assess whether chronic GVHD
had any inﬂuence on RRs. For the 29 patients without
chronic GVHD, the probability of relapse at 3 years
was 41%, whereas the probability of relapse at 3 years
for the 9 patients who did develop chronic GVHD
was 35%. The difference was not signiﬁcant by log-
rank test (P  .55).
DISCUSSION
Most patients with primary refractory AML die
from either disease progression or chemotherapy-re-
lated complications within months from diagnosis.
This long-term follow-up report indicates that ap-
proximately 30% of patients with primary refractory
disease can still be cured with allogeneic SCT. In our
series, the 3-year DFS for patients with intermediate-
risk cytogenetics was 44%, and the outcome was sim-
ilar to that of patients who underwent transplantation
at ﬁrst relapse or second complete remission, despite
the refractory nature of the disease [9,10]. Neverthe-
less, the actual proportion of patients who can be
cured with this approach remains unclear, because
some patients will be excluded from a transplant op-
tion because of poor performance status, active infec-
tion, or inadequate organ function after 1 or more
induction therapies. In addition, many patients cannot
ﬁnd a suitable HLA-matched donor in a timely fash-
ion. This underscores the importance of including
HLA typing as part of the initial assessment for all
patients with AML and also for their potential donors.
Prior studies of allogeneic SCT in patients with
refractory leukemia were associated with high treat-
ment-related toxicity and mortality. In a report from
the International Bone Marrow Transplant Registry
[4], the 3-year treatment-related mortality (TRM) was
44%, and Mehta et al. [11] reported a TRM of 70% in
their series of 24 patients. In our series, despite the
inclusion of 13 patients (18%) who underwent
matched unrelated donor SCT, the overall TRM in
the entire cohort was similar to that of patients who
received an allogeneic SCT at ﬁrst remission [12].
The high TRM in the International Bone Marrow
Transplant Registry study may be due to patient se-
lection, because 25% of patients had clinically signif-
icant infections at the time of transplantation, and
60% of patients had Karnofsky performance scores
90%.
Our initial report and other published single-cen-
ter transplant series were too small to allow identiﬁ-
cation of prognostic factors to predict transplantation
outcome in patients with primary refractory AML.
The largest reported series for this unique group of
patients was from the International Bone Marrow
Transplant Registry [4]. In this study, by univariate
analysis, 25% blasts in the bone marrow before
transplantation, fewer than 4 prior induction regi-
mens, and a Karnofsky performance score 90 were
associated with an improved leukemia-free survival. In
the same report, the presence of circulating blasts at
bone marrow transplantation, female sex, and 25%
blasts in the bone marrow were associated with an
increased risk for relapse. In contrast, none of these
factors was found to be associated with transplantation
outcomes in our analysis. The reasons for the differ-
Figure 4. Kaplan-Meier time to relapse for patients with interme-
diate and unfavorable cytogenetics.
Figure 5. Disease-free survival for patients with related donors
versus unrelated donors. MRD indicates matched related donor;
MUD, matched unrelated donor.
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ences are unclear, but our study suggests that alloge-
neic SCT can overcome the chemoresistance even in
patients with frank leukemia at transplantation (ie,
25% blasts in the bone marrow).
A recent report from the US intergroup [6] has
shown that cytogenetic characteristics present at diag-
nosis are associated not only with responses to induc-
tion therapy in adults with AML, but also with out-
comes of postremission therapy. Cytogenetics are also
the strongest predictive factor for outcomes in pa-
tients with AML who underwent transplantation in
ﬁrst complete remission [13]. Cytogenetic analysis
data, however, were not available in other published
reports for primary acute refractory myelogenous leu-
kemia [4,5,11]. As shown in Figures 3 and 4, this
analysis indicates that cytogenetic characteristics be-
fore SCT correlate with transplantation outcome and
posttransplantation relapse. The presence of unfavor-
able cytogenetics before SCT predicted an adverse
outcome. Our results compare favorably to those of
other reported series [4,5,11], in which 3-year DFS
ranged from 9% to 21%. The differences in the trans-
plantation outcomes may be due to a difference in the
distribution of the cytogenetic risk groups.
The transplantation outcomes for patients who
received an unrelated SCT in this study are poor, with
a 2-year DFS of only 8%. The results, however, are in
accordance with other previously published reports. In
an analysis of 70 patients with AML, the DFS for
patients who underwent transplantation in ﬁrst or
second remission from an unrelated donor was 45%,
and for patients with more advanced disease, DFS was
19% [14]. Sierra et al. [15] from the Fred Hutchinson
Cancer Research Center performed transplantations
in 16 patients with primary induction failure from an
unrelated donor, with 5-year leukemia-free survival
and RRs of 19% and 63%, respectively. The reasons
for the poor outcomes are multifactorial but may in-
clude suboptimal HLA matching, prolonged neutro-
penia before SCT, and repeated salvage attempts with
consequent organ toxicity while a suitable donor was
sought. In our series, the interval between diagnosis
and allogeneic SCT was 3.0 and 4.8 months for the
related donor group and unrelated donor group, re-
spectively (P  .22). In addition, 5 (42%) of 12 unre-
lated transplant recipients received a transplant from a
1 locus–mismatched donor, which has been shown
to adversely affect the transplantation outcomes [16].
Disease progression after transplantation remains
the major cause of treatment failure, in particular for
patients who belong to the unfavorable cytogenetic
risk group. The 3-year probabilities of DFS and re-
lapse were 18% and 57%, respectively, for patients
with unfavorable cytogenetics. The high RRs after
SCT suggest that current high-dose chemoradiation
regimens are often inadequate to eradicate leukemia.
Multiple preparative regimens have been tested in the
phase II setting in an attempt to improve the out-
comes in patients with advanced leukemia, but none of
them has demonstrated any superiority over other
regimens. In a phase III randomized study, the South-
west Oncology Group compared fractionated total
body irradiation and etoposide (FTBI/VP-16) with
busulfan and cyclophosphamide. With a median fol-
low-up of 52 months, the 2-year DFS was 17% and
24% for the TBI/VP-16 arm and the busulfan/cyclo-
phosphamide arm, respectively (P  .81). Newer spe-
ciﬁc antimyeloid conditioning regimens are being
tested. Investigators from the City of Hope Cancer
Center [17] are testing the combination of busulfan,
TBI, and etoposide, with encouraging preliminary re-
sults, and investigators from the Fred Hutchinson
Cancer Research Center are incorporating targeted
radioimmunotherapy into the transplantation regimen
[18,19]. Of note, older age in patients with AML is
often associated with adverse prognostic factors, such
as unfavorable cytogenetics. Thus, they tend to have
refractory disease, and intensifying the regimens may
not be possible; more novel approaches, such as phase
I agents, should be explored.
In conclusion, allogeneic SCT can cure approxi-
mately one third of the patients with primary refrac-
tory AML. Cytogenetic characteristics before SCT
correlate with posttransplantation outcomes and re-
lapse. All patients with AML should be referred for
transplantation evaluation at the ﬁrst sign of treatment
failure to optimize transplantation outcome.
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